<DOC>
	<DOCNO>NCT00454116</DOCNO>
	<brief_summary>The purpose study assess efficacy safety 2 dos ZACTIMA™ ( ZD6474 ) combination FOLFIRI v FOLFIRI alone treatment colorectal cancer patient fail therapy oxaliplatin fluoropyrimidine contain regimen .</brief_summary>
	<brief_title>A Phase II , Double Blind Study 2 Doses ZACTIMA™ ( ZD6474 ) Combination With FOLFIRI v FOLFIRI Alone Treatment Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically confirm colorectal cancer Have fail therapy oxaliplatin fluoropyrimidine contain regimen define : Progression follow treatment metastatic colorectal cancer Progression within 12 month adjuvant chemotherapy colorectal cancer Previous treatment small molecule tyrosine kinase inhibitor VEGFR EGFR eg , erlotinib , gefitinib . Prior monoclonal antibody permit , eg , cetuximab , bevacizumab . Previous adjuvant therapy irinotecan within 12 month randomization More one prior course chemotherapy treatment metastatic colorectal cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
</DOC>